![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
Association of the First Antipsychotic Treatment Duration With the Re-Initiation of Treatment in Schizophrenia: A National Health Insurance Data-Based Study |
Minho Song, Jungsun Lee, Harin Kim, Soojin Ahn, Young Jae Choi, Young Tak Jo, Sung Woo Joo |
Korean J Schizophr Res. 2021;24(2):60-67. Published online October 22, 2021 DOI: https://doi.org/10.16946/kjsr.2021.24.2.60 |
Association of the First Antipsychotic Treatment Duration With the Re-Initiation of Treatment in Schizophrenia: A National Health Insurance Data-Based Study Risk of treatment discontinuation and psychiatric hospitalization associated with early dose reduction of antipsychotic treatment in first‐episode schizophrenia: A nationwide, health insurance data–based study Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: A nationwide, health insurance data-based study Schizophrenia Long-Acting Injectable Antipsychotic Initiation Index: A Clinician Rated Instrument for Improving Treatment in Schizophrenia EFFECTS OF RELAPSE DURATION AND ANTIPSYCHOTIC TREATMENT ON BRAIN TISSUE IN SCHIZOPHRENIA Poster #M224 DURATION OF ANTIPSYCHOTIC MEDICATION TREATMENT IS A MODIFIER FOR WEIGHT GAIN Long-term Antipsychotic Treatment and Brain Volumes: A Longitudinal Study of First-Episode Schizophrenia 23 – Analysis of psychiatric hospitalization after initiation of oral antipsychotic treatment for schizophrenia Study supports continuous antipsychotic treatment for first-episode schizophrenia 24 – Direct healthcare costs after initiation of oral antipsychotic treatment for schizophrenia: Efficacy versus tolerability |